跳至主要内容
临床试验/ACTRN12614000511639
ACTRN12614000511639尚未招募3 期

Prophylactic Ranibizumab in the fellow eye in patients with wet type Age Related Macular Degeneration

El Gawhara eye center ,Egypt0 个研究点目标入组 134 人开始时间: 2014年5月13日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
134

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 80 Years(—)
性别
All

入选标准

  • 1- Must be greater than 50 years of age.
  • 2- Must have a good 5-yr prognosis.
  • 3- Must be diagnosed with age-related macular degeneration.
  • 4- Must be likely to be available, willing, and able to undergo examinations at 6-mo intervals for 5 yrs.
  • 5- Must understand and be willing to give signed informed consent.

排除标准

  • General exclusion criteria :
  • 1-Chronic alcoholism or drug abuse.
  • 2- Personality disorder or use of major tranquilizers (e.g., haloperidol,phenothiazine), indicating difficulty in long-term follow-up.
  • 3- Allergy to sodium fluorescein.
  • Ocular exclusion criteria:
  • 1-For bilateral patients, a BCVA equal to 20/63 on an ETDRS chart in either eye; for unilateral patients, a BCVA equal 20/60 on an ETDRS chart in the eye being considered for treatment.
  • 2- Advanced AMD in either eye for bilateral patients and in both eyes for unilateral patients.
  • 3-A 5 drusen of the specified size within 2250 micron of the center of the fovea in eye(s) being considered for eligibility.
  • 4- Retinopathy due to diabetes mellitus (more than 5 microaneurysms within the temporal Arcades.

研究者

发起方
El Gawhara eye center ,Egypt

相似试验

进行中(未招募)
1 期
Injections into the eye (drug Lucentis) in diabetic patients in whom no further treatment is currently available in clinic when they have developed swelling of the centre of the macula associated with lack of blood supply.Ischaemic Diabetic Macular OedemaMedDRA version: 14.1Level: LLTClassification code 10057915Term: Diabetic macular oedemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10012689Term: Diabetic retinopathySystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10012688Term: Diabetic retinal oedemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10054372Term: Diabetic retinal edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10054109Term: Non-proliferative diabetic retinopathySystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: PTClassification code 10012661Term: Diabetic eye diseaseSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10038925Term: Retinopathy diabeticSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: HLGTClassification code 10012653Term: Diabetic complicationsSystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 14.1Level: HLTClassification code 10012657Term: Diabetic complications ophthalmicSystem Organ Class: 10014698 - Endocrine disorders
EUCTR2013-000031-27-GBMoorfields Eye Hospital80
进行中(未招募)
1 期
Preoperative intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: A randomized, double-masked, controlled study - Vitreous Haemorrhage Study
EUCTR2009-015559-25-GBKing's College Hospital NHS Foundation Trust24
Unknown
2 期
Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy AloneDiabetic Retinopathy
NCT00931125Attila Vajas70
已完成
4 期
A multicentre,open-label,prospective,observational study to evaluate effectiveness and safety of repeated intravitreal injections of Lucentis® in patients with wet age-related macular degeneration over a 12-month observational period in a real-world setting
CTRI/2013/08/003933ovartis India Limited3,000
进行中(未招募)
1 期
Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD
EUCTR2008-004675-22-DEniversity of Bonn20